Bone Biologics Co. (NASDAQ:BBLG – Get Free Report) was the recipient of a large increase in short interest in July. As of July 15th, there was short interest totalling 5,300 shares, an increase of 562.5% from the June 30th total of 800 shares. Approximately 1.0% of the company’s stock are sold short. Based on an average trading volume of 835,900 shares, the short-interest ratio is currently 0.0 days.
Bone Biologics Price Performance
Shares of NASDAQ BBLG traded down $0.10 during mid-day trading on Friday, reaching $1.99. The company had a trading volume of 459,317 shares, compared to its average volume of 2,649,135. The stock has a fifty day moving average of $1.40 and a two-hundred day moving average of $2.20. Bone Biologics has a 12-month low of $1.00 and a 12-month high of $11.76.
Bone Biologics (NASDAQ:BBLG – Get Free Report) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($1.31) EPS for the quarter, beating the consensus estimate of ($7.60) by $6.29. Equities research analysts predict that Bone Biologics will post -5.32 earnings per share for the current fiscal year.
About Bone Biologics
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.
Read More
- Five stocks we like better than Bone Biologics
- 3 REITs to Buy and Hold for the Long Term
- Why Call Options Volume for These 2 Stocks Spiked Together
- How to buy stock: A step-by-step guide for beginners
- MarketBeat Week in Review – 7/22 – 7/26
- How to Most Effectively Use the MarketBeat Earnings Screener
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.